KinoPharma is a clinical-stage biopharmaceutical company focused on developing innovative antiviral treatments, particularly targeting human papillomavirus (HPV) infections that can lead to cervical cancer. The company is actively engaged in research and development of a novel antiviral drug aimed at treating cervical intraepithelial neoplasia (CIN) and common warts caused by HPV. Currently, there are no approved antiviral drugs for CIN, which underscores the significance of KinoPharma's efforts to provide a treatment that can eliminate HPV from the cervix and prevent the progression to cervical cancer. Their clinical candidate is already undergoing trials in Japan and South Korea, with the goal of expediting its approval for patient use.

In addition to its flagship program for CIN, KinoPharma is also exploring treatments for other HPV-related conditions, such as common warts and condyloma acuminatum. The company has initiated Phase II clinical trials for these conditions, reflecting its commitment to addressing a range of medical needs associated with HPV infections. Furthermore, KinoPharma is expanding its research pipeline to include antiviral programs targeting various viral infections, including influenza and dengue fever, as well as exploring potential treatments for neurodegenerative diseases like Alzheimer's. This broad approach highlights KinoPharma's dedication to developing effective antiviral therapies and addressing significant health challenges globally.

Japan

KinoPharma - Developing safe topical treatment for cervical intraepithelial neoplasia (CIN),
human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer.

KinoPharma

Company Details